Sri Chitra Institute develops India’s first flow diverter stent, transfers tech

21 Jan 2021

1

Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST), has entered into technology transfer agreements with Pune-based Biorad Medisys for two biomedical implant devices - an Atrial Septal Defect Occluder and an Intracranial Flow Diverter Stents.

The country’s first indigenous device for correcting ballooning of brain arteries and device for healing of heart hole has been developed by the institute in collaboration with National Aerospace Laboratories, Bangalore (CSIR-NAL) using superelastic NiTiNOL alloys.
CSTIMST is an autonomous institute of the Department of Science & Technology (DST), under the Technical Research Centre (TRC), 
Dr K Jayakumar, director, SCTIMST, and Jitendra Hedge, managing director, Biorad Medisys, signed the technology transfer agreements in the presence of Dr Jitendra J Jadhav, director, CSIR- NAL, through an online meeting early this week.
The novel ASD occlude developed by SCTIMST promotes better healing of the hole in the heart and also has softer edge for minimising the damage to adjacent tissue. The delivery system has a novel release mechanism to enable smooth release of the device. 
The flexible flow diverter stent that allows accurate positioning of the device across the aneurysm developed by SCTIMST is the first one to be manufactured in India. It possesses kink resistance and improved radial strength through a novel braiding pattern making the device flexible and adaptable to the distortion of the vessel boundaries. The device is also provided with radio-opaque markers for radiographic visibility. The associated delivery system allows accurate positioning of the device across the aneurysm. 
The devise and its features have been protected through two Indian patent applications, one international patent application, and design registration. 
The Chitra Flow Diverter stent is expected to be priced significantly lower than the currently imported ones.
Flow diverter stents that are used for diverting blood flow away from localised ballooning of arteries in the brain promotes better healing of the hole in the heart.
Nitinol-based occluder devices, which are currently used to heal Atrial Septal Defect (ASD) or hole in the heart that affects eight out of every 1,000 living babies born, are imported.
Besides, India does not manufacture flow diverter stents, which are needed for diverting blood flow away from an intracranial aneurysm or localised ballooning of arteries in the brain, helping reduce chances of its rupture and related stroke.

Latest articles

Renault bets on Duster revival to rebuild India business with premium SUV push

Renault bets on Duster revival to rebuild India business with premium SUV push

Indian rupee hits fresh record low as importer dollar demand weighs

Indian rupee hits fresh record low as importer dollar demand weighs

Supreme Court issues fresh notice to Anil Ambani, ADAG in PIL alleging ₹1.5 lakh crore fraud

Supreme Court issues fresh notice to Anil Ambani, ADAG in PIL alleging ₹1.5 lakh crore fraud

India targets $1.3 trillion goods exports by 2035 with deregulation-led manufacturing push

India targets $1.3 trillion goods exports by 2035 with deregulation-led manufacturing push

India cancels more South American soy oil imports as rupee slump widens price gap

India cancels more South American soy oil imports as rupee slump widens price gap

Intel warns of AI chip supply crunch; shares slide 13% on weak Q1 2026 forecast

Intel warns of AI chip supply crunch; shares slide 13% on weak Q1 2026 forecast

IndiGo Launches Non-Stop Flights to Athens From Mumbai and Delhi

IndiGo Launches Non-Stop Flights to Athens From Mumbai and Delhi

Trump Sues JPMorgan and CEO Jamie Dimon for $5 Billion Over Alleged Political ‘Debanking’

Trump Sues JPMorgan and CEO Jamie Dimon for $5 Billion Over Alleged Political ‘Debanking’

Micron’s $2.75 Billion Gujarat Chip Facility to Start Commercial Operations by End-February

Micron’s $2.75 Billion Gujarat Chip Facility to Start Commercial Operations by End-February